Pancreatic polypeptide family motifs, polypeptides and methods comprising the same

• US 8,426,361 B2
• Filed: 12/17/2009
• Issued: 04/23/2013
• Est. Priority Date: 02/11/2004
• Status: Expired due to Fees

• Current Assignee: Astrazeneca Pharmaceuticals LP (Astrazeneca PLC)
• Original Assignee: Astrazeneca Pharmaceuticals LP (Astrazeneca PLC), Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Levy, Odile Esther, Jodka, Carolyn M., Ghosh, Soumitra S., Parkes, David G., Pittner, Richard A., D'Souza, Lawrence J., Ahn, John S., Prickett, Kathryn S., Roth, Jonathan David, Adams, Sean H.
• Primary Examiner(s): HEARD, THOMAS SWEENEY
• Application Number:
  US12/640,352
• Publication Number:
  US 20100099619A1
• Time in Patent Office: 1,223 Days
• Field of Search: None
• US Class Current: 514/5.2
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/475 Growth factors; Growth regulators
• CPC Class Codes: C07K 14/575 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695

Abstract

The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.

Claims

1. A PPF polypeptide comprising an amino acid sequence of Formula (VII) (SEQ ID NO:

482);

2. The PPF polypeptide of claim 1, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:

266, 437, 438, 439, 442, 462, 469, 470, 471 and 472.

3. The PPF polypeptide of claim 1, wherein said PPF polypeptide further comprises an N-terminal cap.

4. The PPF polypeptide of claim 2, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:

437, 462, 469, 470 and 472.

5. The PPF polypeptide of claim 1, wherein said polypeptide is linked to one or more water-soluble polymers.

6. The PPF polypeptide of claim 5, wherein said polymer is selected from at least one of the group consisting of polyethylene glycol and a fatty acid molecule, wherein said polymer is linked to the N- or C-terminus of the polypeptide, or the side chain of a lysine or serine amino acid residue within the sequence of the polypeptide.